EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Variation in HPV Vaccination Coverage Across the European Union

Lou Dupont, Jay Brooks Jackson

Trends in Public Health · 2026

DOI: 10.3390/tph1030018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Public Health, 2026. Verfasst von Lou Dupont und 1 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mark Gilbert and Karen Simmons Research Gift Fund.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human papillomavirus (HPV) is the most common sexually transmitted infection globally. While most infections resolve spontaneously, persistent infection with high-risk genotypes (HPV-16 and HPV-18) is causally linked not only to cervical cancer but to a broader spectrum of malignancies, including anal, oral, and oropharyngeal cancers, affecting both women and men. Since its introduction in 2006, the HPV vaccine has proven near-complete efficacy against cervical cancer and approximately 82.7% efficacy against oral and oropharyngeal cancers, establishing vaccination as a cornerstone of cancer prevention. In 2021, Europe’s Beating Cancer Plan set the target of 90% HPV vaccination coverage among girls by 2030, alongside the elimination of cervical cancer (fourth most common cancer in women). All EU/EEA member states now recommend the two-dose HPV vaccination for both adolescent girls and boys within national immunisation programmes, with three countries following the WHO 2022 one-dose regimen guideline (off-label use as the EMA still did not approve it). Five countries have already reached the 90% coverage threshold among girls by age 15. However, despite universal public funding of HPV vaccination across the European Union, the variation of vaccination rates between member states is striking. Uptake ranges from 4% in Bulgaria to 97% in Portugal (2024), with major economies such as France falling below 50%. This paper will try to investigate the current structural, cultural, and programmatic determinants of HPV vaccination differences across EU member states. It will mainly focus on the potential enablers and inhibitors of vaccination: vaccine hesitancy, cervical cancer prevalence, immigration, single-dose regimen adoption, parent support, physician recommendation practices, and school-based vaccination policy.

Förderung

  • Mark Gilbert and Karen Simmons Research Gift Fund

Zitieren

APA

Dupont, L., & Jackson, J. B. (2026). Variation in HPV Vaccination Coverage Across the European Union. Trends in Public Health. https://doi.org/10.3390/tph1030018

Vancouver

Dupont L, Jackson JB. Variation in HPV Vaccination Coverage Across the European Union. Trends in Public Health. 2026. doi:10.3390/tph1030018

BibTeX
@article{Dupont2026,
  author = {Dupont, Lou and Jackson, Jay Brooks},
  title = {Variation in HPV Vaccination Coverage Across the European Union},
  journal = {Trends in Public Health},
  year = {2026},
  doi = {10.3390/tph1030018}
}
Kostenlos starten →